Viking Therapeutics (VKTX) Change in Acquisitions & Divestments (2015 - 2026)

Viking Therapeutics has reported Change in Acquisitions & Divestments for 12 years, with the latest figure at $141.0 million in Q2 2026.

• Quarterly Change in Acquisitions & Divestments fell 15.04% year-over-year to $141.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $565.2 million (down 27.65% YoY) and the FY2025 annual result came in at $759.4 million, up 35.61% from the prior year.
• Change in Acquisitions & Divestments improved to $141.0 million in Q2 2026 per VKTX's latest filing, from $126.6 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $295.9 million in Q1 2025 and troughed at $32.3 million in Q1 2022.
• A 5-year average of $114.6 million and a median of $121.4 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2024 and 2026: Change in Acquisitions & Divestments soared 163.05% in 2024, then slumped 57.2% in 2026.
• Over 5 years, Change in Acquisitions & Divestments stood at $51.9 million in 2022, then soared by 156.94% to $133.3 million in 2023, then increased by 7.71% to $143.5 million in 2024, then dropped by 19.12% to $116.1 million in 2025, then gained by 21.46% to $141.0 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $141.0 million, $126.6 million, and $116.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.